Axitinib

阿昔替尼

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameAxitinib
Drug Alias Name阿西替尼Axitinibum英立达InlytaPF-01367866 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[4] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor +[4] 
Therapy Area/IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[37] 
Global Approved IndicationsCarcinoma, Renal Cell
Approved Indications in ChinaCarcinoma, Renal Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/27
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesLynkcell IncPfizer IncColumbia University +[8] 
Inactive CompaniesSfj Pharma Ltd. IiUniversity of California IrvineChinese University Of Hong Kong (Cuhk) +[17] 
Active IndicationsKidney NeoplasmsProstatic NeoplasmsOvarian Neoplasms +[11] 
Inactive IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[26] 

Other Information

ATC CodeL01EK01
Related LinksWikipediaDrugBankKEGG